PS06. Novel Targets

SATURDAY, NOVEMBER 17, 08:30 ~ 10:10 | Crystal Ballroom

  • Charles L. Sawyers USA

    Memorial Sloan Kettering Cancer Center

  • Young-Joon Surh Korea

    Seoul National University College of Pharmacy

  • 8:30 ~ 8:55

    Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

    Byoung Chul Cho Korea

    Yonsei University College of Medicine

    CV
  • 8:55 ~ 9:20

    Targeting MAT2A in MTAP-deleted cancers

    Katya Marjon USA

    Agios Pharmaceuticals

    CV
  • 9:20 ~ 9:45

    Using organoids to model, detect, and treat cancer

    Senthil K. Muthuswamy USA

    Beth Israel Deaconess Medical Center

    CV
  • 9:45 ~ 10:10

    Targeting DNA damage repair: PARP inhibitor and beyond

    Seock-Ah Im Korea

    Seoul National University College of Medicine

    CV

PS07. Epigenomics

SATURDAY, NOVEMBER 17, 10:40 ~ 12:20 | Crystal Ballroom

  • Patrick Trojer USA

    Constellation Pharmaceuticals

  • Jin-Hyoung Kang Korea

    The Catholic University of Korea

  • 10:40 ~ 11:05

    Precision epigenetic cancer risk diagnosis taking account of our life

    Toshikazu Ushijima Japan

    National Cancer Center

    CV
  • 11:05 ~ 11:30

    Targeting the histone lysine methyltransferase EZH2 in metastatic castrate-resistant prostate cancer

    Patrick Trojer USA

    Constellation Pharmaceuticals

    CV
  • 11:30 ~ 11:55

    Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.

    Bin Teh Singapore

    National Cancer Center

    CV
  • 11:55 ~ 12:20

    Massively scaled single cell whole genome sequencing for studying cancer dynamics

    Sohrab Shah USA

    Memorial Sloan Kettering Cancer Center

Luncheon Symposium 7(MSD)

SATURDAY, NOVEMBER 17, 12:20 ~ 12:50 | Crystal Ballroom

  • Dong-Wan Kim Korea

    Seoul National University Hospital

  • 12:20 ~ 13:00

    The definition of "unprecedented": Unheard-of and unrivaled

    Alena Reznichenko

    MSD/Merck, Asia-Pacific Medical Lead-NSCLC and New Indications

    CV

Special Lecture 3

SATURDAY, NOVEMBER 17, 13:00 ~ 14:00 | Crystal Ballroom

  • Sun Young Rha Korea

    Yonsei University College of Medicine

  • 13:00 ~ 14:00

    Biomarker development strategy for Pembrolizumab in GI tumors

    Mary Josephine Savage USA

    Merck/MSD Research Lab.

    CV

PS08. Immunology: Technologies and Innovations

SATURDAY, NOVEMBER 17, 14:00 ~ 15:40 | Crystal Ballroom

  • Michel Sadelain USA

    Memorial Sloan Kettering Cancer Center

  • Young-Joon Kim Korea

    Department of Chemistry, Yonsei University

  • 14:00 ~ 14:25

    Immune profiling of B lymphocytes in the era of cancer immunotherapy

    Junho Chung Korea

    Seoul National University College of Medicine

  • 14:25 ~ 14:50

    CAR therapy: The CD19 paradigm and beyond

    Michel Sadelain USA

    Memorial Sloan Kettering Cancer Center

    CV
  • 14:50 ~ 15:15

    A personalized cancer vaccine targeting neoepitopes

    Chang-Yuil Kang Korea

    Seoul National University College of Pharmacy

    CV
  • 15:15 ~ 15:25

    Multiplex three-dimensional imaging cytometry for mapping tumor immune microenvironment

    Steve Seung-Young Lee USA

    University of Illinois at Chicago